Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Account Payables (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Change in Account Payables for 9 consecutive years, with -$307000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 136.33% to -$307000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, up 342.16% year-over-year, with the annual reading at $3.7 million for FY2025, 342.16% up from the prior year.
  • Change in Account Payables hit -$307000.0 in Q4 2025 for Protagonist Therapeutics, down from $2.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $9.0 million in Q2 2021 to a low of -$10.3 million in Q3 2021.
  • Historically, Change in Account Payables has averaged $96631.6 across 5 years, with a median of -$47000.0 in 2023.
  • Biggest YoY gain for Change in Account Payables was 8071.68% in 2021; the steepest drop was 3630.93% in 2021.
  • Year by year, Change in Account Payables stood at -$222000.0 in 2021, then crashed by 1679.73% to -$4.0 million in 2022, then skyrocketed by 74.72% to -$999000.0 in 2023, then skyrocketed by 184.58% to $845000.0 in 2024, then tumbled by 136.33% to -$307000.0 in 2025.
  • Business Quant data shows Change in Account Payables for PTGX at -$307000.0 in Q4 2025, $2.4 million in Q3 2025, and $375000.0 in Q2 2025.